Initial AlloNK® (AB-101) clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with...

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

2026-05-08T10:30:00Z

Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no patients...

Nxera Files Patent Infringement Action in Relation to its miniG Platform Technology

2026-05-08T10:26:46Z

Tokyo, Japan and Cambridge and London, UK, 8 May 2026 – Nxera Pharma Co., Ltd. (“Nxera Pharma” or “the Company”; TSE 4565) announces that its wholly owned subsidiary Nxera Pharma...

ANGEL Expands U.S. Water Purification Lineup with New Whole House Water Filtration Systems

2026-05-08T10:20:18Z

LOS ANGELES, May 08, 2026 (GLOBE NEWSWIRE) -- ANGEL, a global water purification brand, today announced an expanded U.S. lineup of home water systems designed to make everyday water—used for...

Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares

2026-05-08T10:00:00Z

ZUG, Switzerland, May 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of...

Profusa Receives Favorable Nasdaq Listing Determination

2026-05-08T10:00:00Z

BERKELEY, CA, May 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a digital health company pioneering the next generation of technology platform enabling the continuous...

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease

2026-05-08T06:30:00Z

TOKYO and CAMBRIDGE, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended...

LifeStance Health Group Announces Pricing of Secondary Public Offering

2026-05-08T02:18:18Z

SCOTTSDALE, Ariz., May 07, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation’s largest providers of virtual and in-person outpatient mental...

Mobia Medical Announces Pricing of Initial Public Offering

2026-05-08T02:10:05Z

AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI) (“Mobia Medical”), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments,...

Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering

2026-05-08T00:44:45Z

BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (“Odyssey”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by...

InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren's Syndrome in China

2026-05-08T00:30:00Z

BEIJING, May 07, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval...

MediPharm Labs Sets Date to Report First Quarter 2026 Financial Results

2026-05-08T00:05:00Z

TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to...

Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-05-07T23:07:21Z

BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), today announced that, on May 3, 2026, the Company granted inducement equity awards to seven new employees, including...

Novi GLP-1 Weight Loss Claims Evaluated: Trusted Semaglutide & Tirzepatide Prescription Medication Treatment Options with Dedicated Doctors

2026-05-07T22:50:39Z

How Compounded Semaglutide, Compounded Tirzepatide, and GLP-1 Telehealth Prescription Weight Loss Programs Work for Eligible Adults in 2026

BioSyent Schedules First Quarter 2026 Earnings Release for May 14, 2026

2026-05-07T22:11:05Z

MISSISSAUGA, Ontario, May 07, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the first quarter ended March 31, 2026...

VitalHub Announces Planned Board Succession with Appointment of Allan Brett as Chairman

2026-05-07T21:55:00Z

TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today proposed changes to its Board of Directors (the “Board”) in connection with the...

VitalHub Reports First Quarter 2026 Results

2026-05-07T21:55:00Z

Annual Recurring Revenue (“ARR”)⁽¹⁾ up 34% YoY to $99.1 millionTotal Revenue up 47% YoY to $31.9 millionAdjusted EBITDA⁽¹⁾ up 42% YoY to $8.0 million

Extendicare Announces 2026 First Quarter Results

2026-05-07T21:24:42Z

MARKHAM, Ontario, May 07, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three months ended March 31, 2026.

LeMaitre to Present at the Bank of America Healthcare Conference

2026-05-07T21:15:30Z

BURLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced today that management will present at the Bank of America Healthcare Conference on Wednesday, May 13,...

Tarsus to Participate in Upcoming Investor Conferences

2026-05-07T21:00:00Z

IRVINE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:

Nova Leap Health Corp. Posts Q1 2026 Results

2026-05-07T21:00:00Z

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

LifeStance Health Group Announces Launch of Secondary Public Offering

2026-05-07T20:51:06Z

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-05-07T20:30:00Z

WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced...

Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases

2026-05-07T20:30:00Z

Six-Month Clinical Data Demonstrate Restoration of Cone-Mediated Vision in Pediatric LCA5 Patients, with Sensitivity Improvements Reaching Normal Ranges